Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

New therapy for depression and other psychotic disorders by combination of selective inhibitor of Serotonin re-uptaking and Galanin N-Terminal Fragment (1–15)

Country of Origin: Spain
Reference Number: TOES20180918002
Publication Date: 18 September 2018

Summary

An Andalusian University in the south of Spain has developed a kit of GAL (1-15) in combination with a serotonin reuptake inhibitor (SRI), which is able to cause an elevation in the level of extracellular serotonin for depression treatment and other anxiety-affective-eating-cognitive disorders. They are looking for pharmaceutical companies that want to enter into a licensing agreement or alternatively technical agreement.

Description

An Andalusian University in the south of Spain has developed a combination kit of GAL (1-15) or a pharmaceutically acceptable salt therof useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin. Particularly, improving and/or potentiating the therapeutic effect of SRI or a compound, which causes an elevation in the level of extracellular 5-HT. The present invention is useful for the treatment of depression, anxiety disorders, and other affective disorders, eating disorders (such as bulimia, anorexia and obesity), phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse.
The clinical studies on depression and anxiety disorders indicate that non-response to Selective Serotonin Reuptake Inhibitors (SSRI) is substantial, up to 30%. Another factor in antidepressant treatment is compliance, which has a rather profound effect on the patient´s motivation to continue pharmacotherapy. There are multiple factors in RRSI use: 1) sexual dysfunction is a side effect common and, 2) there is a delay in therapeutic effect, which the psychiatrists try to cope with an augmentation strategy, which causes other problems.
The results of the kit indicate that GAL (1-15) enhances the antidepressant effects induced by Fluoxetine (FLX) probably acting on 5-HT1AR-GALR1-GALR2 heteroreceptor complexes and open up the possibility to use a combination of both as a novel strategy for treatment of depression.

Advantages and Innovations

Lower doses of SSRIs:
The combination kit of GAL (1-15) with a serotonin reuptake inhibitor shows a synergistic effect on the central nervous system (CNS). As a consequence, combination therapy using GAL (1-15) and lower doses of the serotonin reuptake inhibitor than normally used in monotherapy, may be effective, and side effects associated with the larger amounts or serotonin reuptake inhibitor used in monotherapy may be reduced or prevented altogether.

Alternative for patients, who do not respond to conventional monotherapy:
Additionally, the combination therapy with GAL (1-15) using a normal dose of serotonin reuptake inhibitor has the advantage that an effective CNS effect may be obtained in the often large number of patients who do not respond to conventional monotherapy with SSRIs.

Stage Of Development

Available for demonstration

Requested partner

Pharmaceutical companies that want to enter into a licensing agreement or alternatively technical  agreement in order to explore the new alternative possibility in antidepressant treatments.

Cooperation offer ist closed for requests